Study Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD33 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
Want to learn more about this trial?
Request More InfoInterventions
anti-CD33 CAR T cellsBIOLOGICAL
Anti-CD33 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hebei Yanda Lu Daopei Hospital | Langfang | Hebei | China |